HRP20030961B1 - Novel pyrrole derivatives as pharmaceutical agents - Google Patents

Novel pyrrole derivatives as pharmaceutical agents

Info

Publication number: HRP20030961B1
Authority: HR; Croatia
Prior art keywords: unsubstituted; substituted; alkyl; pyridine; ring
Prior art date: 2001-05-24

Application number

HR20030961A

Other languages

English (en)

Croatian (hr)

Inventor

Scott Sawyer Jason

Wade Beight Douglas

Ciapetti Paola

Vincent Decollo Todd

Glenn Godfrey Alexander

Junior Goodson Theodore

Kent Herron David

Li Hong-Yu

Liao Junkai

Thomas Mcmillen William

Christopher Miller Shawn

Anthony Mort Nicholas

C.R. Smith Edward

Michael Yingling Jonathan

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-24

Filing date

2003-11-21

Publication date

2012-01-31

2003-11-21 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2005-08-31 Publication of HRP20030961A2 publication Critical patent/HRP20030961A2/hr

2012-01-31 Publication of HRP20030961B1 publication Critical patent/HRP20030961B1/xx

Links

239000008177 pharmaceutical agent Substances 0.000 title 1
150000003233 pyrroles Chemical class 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 4
125000005236 alkanoylamino group Chemical group 0.000 abstract 4
-1 aminophenyl Chemical group 0.000 abstract 4
229910052757 nitrogen Inorganic materials 0.000 abstract 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
229910052799 carbon Inorganic materials 0.000 abstract 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 3
238000006467 substitution reaction Methods 0.000 abstract 3
125000001544 thienyl group Chemical group 0.000 abstract 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 2
125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 2
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 abstract 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
GIIWGCBLYNDKBO-UHFFFAOYSA-N Quinoline 1-oxide Chemical class C1=CC=C2[N+]([O-])=CC=CC2=C1 GIIWGCBLYNDKBO-UHFFFAOYSA-N 0.000 abstract 2
125000004423 acyloxy group Chemical group 0.000 abstract 2
125000003302 alkenyloxy group Chemical group 0.000 abstract 2
125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 2
125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
125000001589 carboacyl group Chemical group 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 abstract 2
150000003222 pyridines Chemical class 0.000 abstract 2
150000003248 quinolines Chemical class 0.000 abstract 2
229910052717 sulfur Inorganic materials 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 1
125000005153 alkyl sulfamoyl group Chemical group 0.000 abstract 1
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
150000005528 benzodioxoles Chemical class 0.000 abstract 1
150000001854 cinnolines Chemical class 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000002541 furyl group Chemical class 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000002883 imidazolyl group Chemical group 0.000 abstract 1
UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 abstract 1
150000002790 naphthalenes Chemical class 0.000 abstract 1
150000005054 naphthyridines Chemical class 0.000 abstract 1
125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical class C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 abstract 1
150000003216 pyrazines Chemical class 0.000 abstract 1
125000003226 pyrazolyl group Chemical group 0.000 abstract 1
150000003230 pyrimidines Chemical class 0.000 abstract 1
150000003246 quinazolines Chemical class 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
125000000335 thiazolyl group Chemical group 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Virology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)

HR20030961A 2001-05-24 2003-11-21 Novel pyrrole derivatives as pharmaceutical agents HRP20030961B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29346401P	2001-05-24	2001-05-24
PCT/US2002/011884 WO2002094833A1 (en)	2001-05-24	2002-05-13	Novel pyrrole derivatives as pharmaceutical agents

Publications (2)

Publication Number	Publication Date
HRP20030961A2 HRP20030961A2 (en)	2005-08-31
HRP20030961B1 true HRP20030961B1 (en)	2012-01-31

Family

ID=23129192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20030961A HRP20030961B1 (en)	2001-05-24	2003-11-21	Novel pyrrole derivatives as pharmaceutical agents

Country Status (38)

Country	Link
US (1)	US7087626B2 (xx)
EP (1)	EP1397364B1 (xx)
JP (2)	JP4519407B2 (xx)
KR (1)	KR100861630B1 (xx)
CN (2)	CN1269820C (xx)
AR (1)	AR036034A1 (xx)
AT (1)	ATE368041T1 (xx)
AU (1)	AU2002339268B2 (xx)
BR (1)	BR0209939A (xx)
CA (1)	CA2446820C (xx)
CO (1)	CO5540282A2 (xx)
CY (1)	CY1106871T1 (xx)
CZ (1)	CZ303808B6 (xx)
DE (1)	DE60221392T2 (xx)
DK (1)	DK1397364T3 (xx)
DZ (1)	DZ3506A1 (xx)
EA (1)	EA007782B1 (xx)
EC (1)	ECSP034859A (xx)
EG (1)	EG25614A (xx)
ES (1)	ES2289116T3 (xx)
HK (1)	HK1064375A1 (xx)
HR (1)	HRP20030961B1 (xx)
HU (1)	HU228844B1 (xx)
IL (2)	IL158512A0 (xx)
MX (1)	MXPA03010630A (xx)
MY (1)	MY134586A (xx)
NO (1)	NO326701B1 (xx)
NZ (1)	NZ528525A (xx)
PE (1)	PE20030117A1 (xx)
PL (1)	PL221339B1 (xx)
PT (1)	PT1397364E (xx)
SI (1)	SI1397364T1 (xx)
SK (1)	SK287857B6 (xx)
SV (1)	SV2003001054A (xx)
TW (1)	TWI329644B (xx)
UA (1)	UA76461C2 (xx)
WO (1)	WO2002094833A1 (xx)
ZA (1)	ZA200308546B (xx)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA76461C2 (en) *	2001-05-24	2006-08-15	Lilly Co Eli	Pyrrazole derivatives as pharmaceutical agents, use thereof, a pharmaceutical composition on their basis
ATE373000T1 (de) *	2001-12-11	2007-09-15	Smithkline Beecham Corp	Pyrazolopyridin-derivate als antiherpesmittel
ATE370139T1 (de) *	2002-09-17	2007-09-15	Lilly Co Eli	Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
AU2003298611A1 (en) *	2002-11-21	2004-06-18	Eli Lilly And Company	Mixed lineage kinase modulators
US20060079680A1 (en) *	2002-11-22	2006-04-13	Eli Lilly And Company Patent Division	Pyrazoloazepine compounds as pharmaceutical agents
UA80571C2 (en) *	2002-11-22	2007-10-10	Lilly Co Eli	Quinolinyl-pyrrolopyrazoles
EP1567527A1 (en)	2002-11-27	2005-08-31	Eli Lilly And Company	Condensed pyrazolo derivatives
CL2004000234A1 (es) *	2003-02-12	2005-04-15	Biogen Idec Inc	Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7511065B2 (en)	2003-11-12	2009-03-31	Eli Lilly And Company	Mixed lineage kinase modulators
US7368445B2 (en)	2004-03-01	2008-05-06	Eli Lilly And Company	Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms
TW200639163A (en) *	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
US7977354B2 (en)	2005-04-01	2011-07-12	Insa Rouen	Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
PL1910370T3 (pl) *	2005-07-22	2015-09-30	Lilly Co Eli	Monohydrat pirolo [1,2-b] pirazolu podstawionego pirydynochinoliną jako inhibitor tgf-beta
US7608635B2 (en)	2005-08-12	2009-10-27	Synta Pharmaceuticals Corp.	Pyrazole compounds that modulate HSP90 activity
EP1973909A2 (en) *	2005-12-22	2008-10-01	Biogen Idec MA Inc.	Transforming growth factor modulators
DE102005061840A1 (de) *	2005-12-23	2007-06-28	Merck Patent Gmbh	Triazolderivate
AU2007267843B2 (en)	2006-05-25	2011-10-13	Synta Pharmaceuticals Corp.	Method for treating proliferative disorders associated with protooncogene products
CN104645328A (zh)	2006-10-03	2015-05-27	建新公司	TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
PE20090717A1 (es)	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
PL2217600T3 (pl)	2007-12-12	2013-04-30	Du Pont	Grzybobójcze pirazole bicykliczne
ES2422263T3 (es) *	2008-12-19	2013-09-10	Nerviano Medical Sciences Srl	Pirazoles bicíclicos como inhibidores de la proteinquinasa
EP2419105A4 (en) *	2009-04-17	2012-09-12	Summa Health Systems Llc	USE OF TRANSFORMATION OF GROWTH FACTOR B RECEPTOR INHIBITORS TO SUPPRESS OCULAR HEALING
AR081810A1 (es) *	2010-04-07	2012-10-24	Bayer Cropscience Ag	Piridinilpirazoles biciclicos
US9205086B2 (en)	2010-04-19	2015-12-08	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
EP2402337A1 (en) *	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridine compounds
EP2402340A1 (en)	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridine compounds
EP2401915A1 (en)	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridine compounds
EP2402338A1 (en)	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridine compounds
EP2402339A1 (en) *	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridine compounds
US8871744B2 (en)	2010-07-21	2014-10-28	B & G Partyers, LLC	Compounds and methods for selectively targeting tumor-associated mucins
WO2012138945A1 (en)	2011-04-08	2012-10-11	Aestus Therapeutics, Inc.	Methods of treating schizophrenia with pyrazole derivative inhibitors of tgf - beta
EP2737083A1 (en)	2011-07-27	2014-06-04	INSERM (Institut National de la Santé et de la Recherche Scientifique)	Methods for diagnosing and treating myhre syndrome
MX2014004994A (es)	2011-10-26	2014-08-27	Seattle Children S Res Inst	Cisteamina en el tratamiento de enfermedad fibrotica.
AU2012332421A1 (en)	2011-11-02	2014-06-05	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors
CA2853806C (en)	2011-11-02	2020-07-14	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en)	2011-11-14	2013-05-23	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with braf inhibitors
US9782452B2 (en)	2011-11-22	2017-10-10	Cornell University	Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
CN109160950B (zh)	2012-10-05	2022-10-04	卡德门企业有限公司	人抗vegfr-2/kdr抗体
TWI443096B (zh)	2012-12-18	2014-07-01	Ind Tech Res Inst	３－（５－（４－（３－氟丙基）哌嗪－１－基）苯並咪唑－２－基）－１－氮雜薁－２－酮之單水合晶型及其製備方法與藥學組成物
CA2900300A1 (en) *	2013-02-07	2014-08-14	Merck Patent Gmbh	Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
US10041046B2 (en)	2013-03-14	2018-08-07	Massachusetts Institute Of Technology	Compositions and methods for epithelial stem cell expansion and culture
US8975417B2 (en) *	2013-05-27	2015-03-10	Novartis Ag	Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EP3527569B1 (en)	2014-02-03	2021-08-25	Vitae Pharmaceuticals, LLC	Dihydropyrrolopyridine inhibitors of ror-gamma for use in treating drye eye
AU2015311816B2 (en)	2014-09-03	2019-04-04	Massachusetts Institute Of Technology	Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
TWI582083B (zh)	2014-10-07	2017-05-11	美國禮來大藥廠	胺基吡啶基氧基吡唑化合物
US9663515B2 (en)	2014-11-05	2017-05-30	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
ES2918924T3 (es)	2015-04-01	2022-07-21	Rigel Pharmaceuticals Inc	Inhibidores de TGF-beta
WO2016210292A1 (en)	2015-06-25	2016-12-29	Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US10301261B2 (en)	2015-08-05	2019-05-28	Vitae Pharmaceuticals, Llc	Substituted indoles as modulators of ROR-gamma
US11008340B2 (en) *	2015-11-20	2021-05-18	Vitae Pharmaceuticals, Llc	Modulators of ROR-gamma
JP2019506153A (ja)	2016-01-08	2019-03-07	マサチューセッツインスティテュートオブテクノロジー	分化した腸内分泌細胞およびインスリン産生細胞の作製
TW202220968A (zh)	2016-01-29	2022-06-01	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
US10213511B2 (en)	2016-03-02	2019-02-26	Frequency Therapeutics, Inc.	Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en)	2016-03-02	2022-03-01	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en)	2016-03-02	2019-02-12	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
EP3429603B1 (en)	2016-03-15	2021-12-29	Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion
US10548883B2 (en) *	2016-06-13	2020-02-04	Genfleet Therapeutics (Shanghai) Inc.	Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor
SG11201901773QA (en)	2016-07-29	2019-04-29	Shanghai Yingli Pharmaceutical Co Ltd	Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
AU2017386417B2 (en)	2016-12-30	2022-07-14	Frequency Therapeutics, Inc.	1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
CN110612100B (zh) *	2017-05-05	2023-04-14	艾库斯生物科学有限公司	治疗与癌症有关疾病的喹唑啉-吡啶衍生物
MX2020000887A (es)	2017-07-24	2020-07-22	Vitae Pharmaceuticals Llc	Inhibidores de ror?.
WO2019018975A1 (en)	2017-07-24	2019-01-31	Vitae Pharmaceuticals, Inc.	INHIBITORS OF ROR GAMMA
AU2018346712B2 (en)	2017-10-05	2021-04-01	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
AU2018348930A1 (en)	2017-10-11	2020-03-26	F. Hoffmann-La Roche Ag	Bicyclic compounds for use as RIP 1 kinase inhibitors
JP2021035911A (ja) *	2017-11-15	2021-03-04	大日本住友製薬株式会社	縮環ピラゾール誘導体及びその医薬用途
CN111479809B (zh)	2017-12-13	2021-10-29	劲方医药科技(上海)有限公司	一种TGF-βRI抑制剂的晶型、盐型及其制备方法
CN110066276B (zh)	2018-01-24	2020-09-18	上海璎黎药业有限公司	芳香杂环化合物、其中间体、制备方法、药物组合物和应用
CN110066277B (zh)	2018-01-24	2021-07-23	上海璎黎药业有限公司	芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
CA3093340A1 (en)	2018-03-20	2019-09-26	Icahn School Of Medicine At Mount Sinai	Kinase inhibitor compounds and compositions and methods of use
US20210254006A1 (en)	2018-06-06	2021-08-19	Ideaya Biosciences, Inc.	Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
EP3827010A4 (en) *	2018-07-23	2022-03-16	Brise Pharmaceuticals Co., Ltd.	BISPHOSPHONATE-DRUG CONJUGATES
US11617745B2 (en)	2018-08-17	2023-04-04	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by downregulating FOXO
AU2019321641A1 (en)	2018-08-17	2021-04-15	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by upregulating Jag-1
CN112839946B (zh) *	2018-10-31	2022-04-12	江苏奥赛康药业有限公司	作为TGF-βR1激酶抑制剂的双环吡唑类化合物
JP7466128B2 (ja) *	2018-11-22	2024-04-12	フンダシオインスティテュートデレセルカビオメディカ（アイアールビーバルセロナ）	ＴＧＦβ阻害剤およびプロドラッグ
MX2021007738A (es)	2018-12-27	2021-08-05	Nexys Therapeutics Inc	Derivados de (piridin-2-il)amina como inhibidores de tgf-beta r1 (alk5) para el tratamiento de cancer.
AU2019419414A1 (en)	2018-12-31	2023-04-06	Icahn School Of Medicine At Mount Sinai	Kinase inhibitor compounds and compositions and methods of use
JP7331116B2 (ja)	2019-01-24	2023-08-22	チアンスーアオサイカンファーマシューティカルカンパニー，リミティド	ＴＧＦ－βＲ１キナーゼ阻害剤としての５－（４－ピリジルオキシ）ピラゾール類化合物
WO2020160151A1 (en) *	2019-01-31	2020-08-06	Kyorin Pharmaceutical Co., Ltd.	15-pgdh inhibitors
WO2020201362A2 (en)	2019-04-02	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020248908A1 (zh) *	2019-06-10	2020-12-17	中国科学院广州生物医药与健康研究院	一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
WO2021142086A1 (en)	2020-01-08	2021-07-15	Synthis Therapeutics, Inc.	Alk5 inhibitor conjugates and uses thereof
CN114867723B (zh) *	2020-07-23	2023-05-30	江苏奥赛康药业有限公司	作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
WO2022063050A1 (zh)	2020-09-28	2022-03-31	四川科伦博泰生物医药股份有限公司	吡唑类化合物及其制备方法和用途
CN115703750A (zh) *	2021-08-17	2023-02-17	黑龙江华瑞生物科技有限公司	一种1-氨基-4-甲基哌嗪的提取纯化方法
CN114249742B (zh) *	2021-11-22	2022-11-01	郑州大学	一种光气探针、荧光书写检测笔及其在光气检测中的应用
CN115969801B (zh) *	2023-03-21	2023-08-25	劲方医药科技(上海)有限公司	用于癌症的药物组合物及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0531901A2 (en) *	1991-09-09	1993-03-17	Fujisawa Pharmaceutical Co., Ltd.	Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity
US5358947A (en) *	1993-09-13	1994-10-25	American Cyanamid Company	Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones
EP0666079A1 (en) *	1993-07-27	1995-08-09	Kyowa Hakko Kogyo Co., Ltd.	Remedy for parkinson's disease
WO1997003551A1 (en) *	1995-07-17	1997-02-06	Rossmarg Pty. Ltd.	Plant protectors
US5670503A (en) *	1993-02-26	1997-09-23	Fujisawa Pharmaceutical Co., Ltd.	Pyrazole derivatives
EP0923929A1 (fr) *	1997-12-16	1999-06-23	L'oreal	Compositions de teinture des fibres kératiniques centenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procédé de teinture; nouveaux pyrazolo-azoles
WO2000044743A1 (fr) *	1999-01-28	2000-08-03	Nippon Shinyaku Co., Ltd.	Derives d'amides et compositions de medicaments
WO2001016138A1 (en) *	1999-08-27	2001-03-08	Abbott Laboratories	Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE177426T1 (de) *	1992-06-17	1999-03-15	Upjohn Co	Pyrridino-, pyrrolidino- und azepino- substituierte oxime als antiatherosklerosemittel und antihypercholesterolemiemittel
FR2746306B1 (fr)	1996-03-22	1998-04-30	Oreal	Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles ; leur utilisation pour la teinture comme coupleurs, procede de teinture
ID22982A (id)	1997-05-22	1999-12-23	Searle & Co	PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38
GB9809869D0 (en)	1998-05-09	1998-07-08	Medical Res Council	Inhibition of protein kinases
DE60001229T2 (de)	1999-04-09	2003-10-30	Smithkline Beecham Corp	Triarylimidazole
GB0007405D0 (en)	2000-03-27	2000-05-17	Smithkline Beecham Corp	Compounds
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US7125887B2 (en) *	2000-10-11	2006-10-24	Merck & Co., Inc.	Pyrrolidine modulators of CCR5 chemokine receptor activity
ATE291020T1 (de)	2001-02-02	2005-04-15	Smithkline Beecham Corp	Pyrazolderivate gegen tgf überexprimierung
UA76461C2 (en) *	2001-05-24	2006-08-15	Lilly Co Eli	Pyrrazole derivatives as pharmaceutical agents, use thereof, a pharmaceutical composition on their basis
DK1633912T3 (da) *	2003-05-28	2014-10-06	Oerlikon Textile Gmbh & Co Kg	En fremgangsmåde og en fiberfordeler til at tørlægge fibre
JP4882198B2 (ja)	2003-09-25	2012-02-22	日産自動車株式会社	燃料電池システム

2002
- 2002-05-13 UA UA20031110606A patent/UA76461C2/uk unknown
- 2002-05-13 NZ NZ528525A patent/NZ528525A/en not_active IP Right Cessation
- 2002-05-13 EA EA200301289A patent/EA007782B1/ru not_active IP Right Cessation
- 2002-05-13 HU HU0400451A patent/HU228844B1/hu not_active IP Right Cessation
- 2002-05-13 AU AU2002339268A patent/AU2002339268B2/en not_active Ceased
- 2002-05-13 ES ES02744115T patent/ES2289116T3/es not_active Expired - Lifetime
- 2002-05-13 CN CNB028105087A patent/CN1269820C/zh not_active Expired - Fee Related
- 2002-05-13 CZ CZ20033128A patent/CZ303808B6/cs not_active IP Right Cessation
- 2002-05-13 WO PCT/US2002/011884 patent/WO2002094833A1/en active IP Right Grant
- 2002-05-13 PL PL367199A patent/PL221339B1/pl unknown
- 2002-05-13 CN CNA2006100946748A patent/CN1951939A/zh active Pending
- 2002-05-13 SI SI200230626T patent/SI1397364T1/sl unknown
- 2002-05-13 SK SK1416-2003A patent/SK287857B6/sk not_active IP Right Cessation
- 2002-05-13 DE DE60221392T patent/DE60221392T2/de not_active Expired - Lifetime
- 2002-05-13 AT AT02744115T patent/ATE368041T1/de active
- 2002-05-13 JP JP2002591506A patent/JP4519407B2/ja not_active Expired - Fee Related
- 2002-05-13 KR KR1020037015226A patent/KR100861630B1/ko not_active IP Right Cessation
- 2002-05-13 CA CA2446820A patent/CA2446820C/en not_active Expired - Fee Related
- 2002-05-13 PT PT02744115T patent/PT1397364E/pt unknown
- 2002-05-13 EP EP02744115A patent/EP1397364B1/en not_active Expired - Lifetime
- 2002-05-13 DK DK02744115T patent/DK1397364T3/da active
- 2002-05-13 IL IL15851202A patent/IL158512A0/xx unknown
- 2002-05-13 MX MXPA03010630A patent/MXPA03010630A/es active IP Right Grant
- 2002-05-13 BR BR0209939-0A patent/BR0209939A/pt not_active Application Discontinuation
- 2002-05-13 US US10/477,111 patent/US7087626B2/en not_active Expired - Fee Related
- 2002-05-15 DZ DZ023506A patent/DZ3506A1/fr active
- 2002-05-22 EG EG2002050542A patent/EG25614A/xx active
- 2002-05-24 SV SV2002001054A patent/SV2003001054A/es unknown
- 2002-05-24 PE PE2002000435A patent/PE20030117A1/es not_active Application Discontinuation
- 2002-05-24 MY MYPI20021941A patent/MY134586A/en unknown
- 2002-05-24 TW TW091111082A patent/TWI329644B/zh not_active IP Right Cessation
- 2002-05-27 AR ARP020101974A patent/AR036034A1/es not_active Application Discontinuation
2003
- 2003-10-20 IL IL158512A patent/IL158512A/en not_active IP Right Cessation
- 2003-10-31 ZA ZA2003/08546A patent/ZA200308546B/en unknown
- 2003-11-18 CO CO03101666A patent/CO5540282A2/es active IP Right Grant
- 2003-11-21 NO NO20035193A patent/NO326701B1/no not_active IP Right Cessation
- 2003-11-21 EC EC2003004859A patent/ECSP034859A/es unknown
- 2003-11-21 HR HR20030961A patent/HRP20030961B1/xx not_active IP Right Cessation
2004
- 2004-09-15 HK HK04107054A patent/HK1064375A1/xx not_active IP Right Cessation
2007
- 2007-09-17 CY CY20071101193T patent/CY1106871T1/el unknown
2009
- 2009-04-27 JP JP2009108167A patent/JP2009197016A/ja active Pending

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0531901A2 (en) *	1991-09-09	1993-03-17	Fujisawa Pharmaceutical Co., Ltd.	Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity
US5670503A (en) *	1993-02-26	1997-09-23	Fujisawa Pharmaceutical Co., Ltd.	Pyrazole derivatives
EP0666079A1 (en) *	1993-07-27	1995-08-09	Kyowa Hakko Kogyo Co., Ltd.	Remedy for parkinson's disease
US5358947A (en) *	1993-09-13	1994-10-25	American Cyanamid Company	Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones
WO1997003551A1 (en) *	1995-07-17	1997-02-06	Rossmarg Pty. Ltd.	Plant protectors
EP0923929A1 (fr) *	1997-12-16	1999-06-23	L'oreal	Compositions de teinture des fibres kératiniques centenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procédé de teinture; nouveaux pyrazolo-azoles
WO2000044743A1 (fr) *	1999-01-28	2000-08-03	Nippon Shinyaku Co., Ltd.	Derives d'amides et compositions de medicaments
WO2001016138A1 (en) *	1999-08-27	2001-03-08	Abbott Laboratories	Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors

Also Published As

Publication number	Publication date
EP1397364B1 (en)	2007-07-25
IL158512A (en)	2009-07-20
JP2009197016A (ja)	2009-09-03
CN1269820C (zh)	2006-08-16
TWI329644B (en)	2010-09-01
NO326701B1 (no)	2009-02-02
HUP0400451A2 (hu)	2004-12-28
CA2446820A1 (en)	2002-11-28
HK1064375A1 (en)	2005-01-28
DE60221392T2 (de)	2008-04-17
NO20035193L (no)	2003-11-21
SK14162003A3 (en)	2004-11-03
PL367199A1 (en)	2005-02-21
DE60221392D1 (de)	2007-09-06
US7087626B2 (en)	2006-08-08
HU228844B1 (en)	2013-06-28
ES2289116T3 (es)	2008-02-01
HUP0400451A3 (en)	2008-08-28
CY1106871T1 (el)	2012-09-26
CN1511157A (zh)	2004-07-07
UA76461C2 (en)	2006-08-15
MY134586A (en)	2007-12-31
NZ528525A (en)	2005-10-28
WO2002094833A1 (en)	2002-11-28
CZ303808B6 (cs)	2013-05-09
PE20030117A1 (es)	2003-02-12
PT1397364E (pt)	2007-10-22
ECSP034859A (es)	2004-01-28
CO5540282A2 (es)	2005-07-29
DK1397364T3 (da)	2007-11-26
SI1397364T1 (sl)	2007-12-31
CA2446820C (en)	2010-07-13
CZ20033128A3 (cs)	2004-06-16
BR0209939A (pt)	2004-03-30
DZ3506A1 (fr)	2002-11-28
EA007782B1 (ru)	2007-02-27
PL221339B1 (pl)	2016-03-31
EA200301289A1 (ru)	2004-06-24
ZA200308546B (en)	2005-04-26
KR100861630B1 (ko)	2008-10-07
AR036034A1 (es)	2004-08-04
US20040106604A1 (en)	2004-06-03
IL158512A0 (en)	2004-05-12
EP1397364A1 (en)	2004-03-17
KR20030097895A (ko)	2003-12-31
CN1951939A (zh)	2007-04-25
MXPA03010630A (es)	2004-03-09
EG25614A (en)	2012-03-22
HRP20030961A2 (en)	2005-08-31
SV2003001054A (es)	2003-03-18
JP4519407B2 (ja)	2010-08-04
NO20035193D0 (no)	2003-11-21
AU2002339268B2 (en)	2007-05-31
ATE368041T1 (de)	2007-08-15
JP2004535404A (ja)	2004-11-25
SK287857B6 (sk)	2012-01-04

Legal Events

Date	Code	Title	Description
2005-08-31	A1OB	Publication of a patent application
2006-01-11	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2012-01-31	B1PR	Patent granted
2017-05-09	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20170509 Year of fee payment: 16
2018-11-23	PBON	Lapse due to non-payment of renewal fee	Effective date: 20180513

Publication	Publication Date	Title
HRP20030961B1 (en)	2012-01-31	Novel pyrrole derivatives as pharmaceutical agents
EP1344525A4 (en)	2005-05-25	ANILINE DERIVATIVES OR ITS SALTS AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THEM
YU48803A (sh)	2006-05-25	Derivati tetrahidropiridina,njihovo dobijanje i primena kao inhibitora za proliferaciju ćelija
NZ586418A (en)	2012-09-28	Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
CA2385859A1 (en)	2001-04-12	2'-substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them
CA2430273A1 (en)	2002-06-06	Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them
CA2436891A1 (en)	2002-06-13	Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
MY110886A (en)	1999-06-30	Stereoselective preparation of substituted piperidines.
GB1088531A (en)	1967-10-25	Substituted benzamides
EP1156045A4 (en)	2002-04-17	AMID DERIVATIVES AND DRUG COMPOSITIONS
EP1535922A4 (en)	2006-10-04	PYRROLOPYRIDINE DERIVATIVE AND ITS USE
RU2005135338A (ru)	2007-05-27	Замещенные 3-цианотиофенацетамиды в качестве антагонистов рецептора глюкагона
GB1402498A (en)	1975-08-06	Triazine derivatives their production and their medicinal use
KR880008987A (ko)	1988-09-13	헤테로아릴 3-옥소-프로판니트릴 유도체 및 그의 제조방법
CA2084163A1 (en)	1993-06-05	Endothelin antagonistic substance
EP0596126A4 (en)	1994-06-08	Novel quinolone derivative or salt thereof and antibacterial containing the same.
IL126110A0 (en)	1999-05-09	Use of aryl n-substituted carboxamides to kill tumors and novel compounds for such use
CA2108356A1 (en)	1993-09-27	Antibiotic compounds
WO2003068744A1 (fr)	2003-08-21	Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives
KR870007105A (ko)	1987-08-14	살충제 n'-치환-n-알킬카르보닐-n-아실히드라진
RU2307829C2 (ru)	2007-10-10	Карбоксамидные производные амидного типа
CA2373944A1 (en)	2000-12-07	Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
CA2380757A1 (en)	2001-02-22	Pharmaceutical agent comprising a benzamide derivative as active ingredient
DE60316436D1 (de)	2007-10-31	Amidderivate als inhibitoren der enzymatischen aktivität von renin
CA2326045A1 (en)	1999-10-07	Pde iv inhibiting pyridine derivatives